We have an excellent network of internationally renowned key opinion leaders at hand. We use this pool of knowledge to enhance cancer therapy. Starting from treatment optimization via drug development up to faster drug availability for the patient – we regard cancer therapy in its entirety.
Fighting cancer needs genius and expertise – but prior to all it needs cooperation.
Ahmet Sami Pekkip – Chief Executive Officer
PEKKIP Oncology Alliance: a portrait
Prof Dr Christian Manegold, Ahmet Pekkip and their team about company objectives, fast-track development of active substances and the longterm strategy of PEKKIP Oncology Alliance AG in Europe, Asia and America.
The shortest way to your success.
Professional consultation in the field of in-licensing and out-licensing.
What we offer:
Screening of clinical development candidates and identification of promising active substances / development platforms
Initial contact to potential partners in Europe, USA and/or China
Accompanying the development up to defined milestones
Observation and verification of current trials
Let Us Give You an Example:
A research team develops a promising active substance for lung cancer therapy. Together with the research team we will give a first evaluation.
In a second step we will run the active substance through our network. This network consists of hundreds of high-ranking key opinion leaders: clinical practitioners, scientific medical experts and pharmaceutical business insiders with long-time commercial expertise.
Our board of directors will assess and evaluate the network’s feedback. At an individually defined success forecast rate we approach pharma companies and offer them to further develop the active substance and bring it to the market.
Knowledge, expertise and timing are the keys to a successful product launch.
Prof Dr Christian Manegold – Senior Director Medical Affairs
Our best experts for your project.
We offer advice in scientific monitoring, exchange and support.
We consult and accompany drug development over a desired period of time, at which the extent of consultation can be adjusted as necessary. Your benefit: our network of international key opinion leaders is independent and unbiased, so we are able to ensure fast and efficient consulting processes.
To give you the best scientific support for your development, we also offer:
We organize advisory boards with internationally renowned key opinion leaders for the pharma industry with topics ranging from evaluation of active substances to product marketing.
We offer advanced on-site trainings for academic and non-academic personnel by internationally renowned key opinion leaders.
We support you and your project in the field of funding and project management. We can also help you with fast recruiting for and managing of the clinical trial. We identify appropriate laboratories/research centers. Furthermore we build and lead research and medical affairs departments.
You can’t be an expert in every scientific sector – but you have to know who it is.
Dr Klaus Herdrich – Senior Associate Medical Affairs
Tailormade financing for your needs.
We partner up with you to ensure your development won’t stagnate.
In addition to finding promising partners for drug development, we also consider becoming a partner ourselves. After a first evaluation we offer to invest venture capital and accompany the project with our scientific expertise.
Our aim: to push the clinical development at an early stage (Phase I/II) and to reach the next milestone. We are not interested in launching the product itself. In our understanding the potential of a promising active substance can only be fully tapped by a large international pharma company. Our aim is to outlicense the active substance at a later stage.
Ahmet Pekkip began his versatile career in 1975 as construction superintendent for the US Army in Heidelberg, Germany. He finished university in 1981 with a graduate degree as industrial engineer in Philadelphia, USA. In 1985 he earned a lecturer degree for civil engineering seminars.
Since 2001 Ahmet Pekkip has been active in project development in the public health sector. In 2011 he took over the management and operation of hospitals, mainly the Rhein-Jura Klinik Bad Säckingen, Germany, a private psychiatric and psychosomatic clinic that he lead to unsuspected yet ongoing success.
In 2014 Ahmet Pekkip founded Xenios Oncology Advice AG, which was renamed into PEKKIP Oncology Alliance AG in 2016.
Together with Prof Dr Manegold and the PEKKIP Congress GmbH we lead and organize the annual Chinese-German Lung Cancer Forum (CGLCF) and the International Thoracic Oncology Congress (ITOCD), which enhances and simplifies our interaction with international pharmaceutical companies.
Prof Dr Manegold is a former head of Thoracic Oncology at Interdisciplinary Tumor Center Mannheim, Germany, and a former chairman of EORTC-LCCG and IASLC board member. He has experience as a clinical investigator, national and international trial leader as well as a member or leader of independent data monitoring committees (IDMC) in numerous clinical trials in Oncology in thoracic cancer and other indications since 1989.
Since we founded Xenios in 2014, today known as PEKKIP Oncology Alliance, he leads our team as Senior Director Medical Affairs.
Dr Klaus Herdrich studied Biology and Geography at Karlsruhe University, Germany, followed till 1981 by a Doctorate in Microbiology and an Assistant position at the Botanical Institute in Karlsruhe.
He then switched to the pharmaceutical industry (ASTA Medica, Baxter) holding various positions in Global Medical and Marketing Departments with a focus on Medical and Scientific Information Oncology. In the course of his working life he authored and co-authored more than 50 journal articles, brochures and book chapters.
Mid-2015 he retired, joined the Xenios team and now works for the PEKKIP Oncology Alliance.
Parallel to her studies at the Frankfurt Conservatory, Lale Jakob took over the position of General Managing Director of the International Katarzyna Mycka Marimba Academy in 2009.
She received her diploma and proceeded to study Controlling, Management and Information in Ludwigshafen/Rhine, Germany. While writing her bachelor thesis she was working in the marketing department at expopharm in Eschborn near Frankfurt, Germany.
Lale Jakob started her career in the marketing department of Xenios Oncology Advice AG. In 2015 she was appointed Senior Associate Commercial Relations for Xenios. Since 2016 she is the Senior Associate Commercial Relations at PEKKIP Oncology Alliance.
Jingrui (Johannes) Yang obtained his bachelor degree in pharmacy from Fudan University in 2001 and an MBA degree from Cardiff University in 2003.
Yang used to work for AstraZeneca China as brand manager for IRESSA. He also worked in the marketing and sales departments of GlaxoSmithKline and Novartis.
He is also the founder and CEO of ProMedican, a leading professional medical consultant and service company in China. Since 2015 ProMedican is the exclusive co-operation partner of PEKKIP Oncology Alliance in Shanghai.
There lies huge responsibility in developing an active substance for cancer therapy – but also a great chance.
Lale Jakob – Senior Associate Commercial Relations
Always well informed.
With our news portal we keep you informed about upcoming events and recent news all around the PEKKIP Oncology Alliance.
November 23, 2017
Rowing against cancer 2017
Lale Jakob, CEO of PEKKIP Holding and Senior Associate Commercial Relations of PEKKIP Oncology Alliance takes pride in her great …View Article
September 15, 2016
8th Chinese-German Lung Cancer Forum
Every two years, the Chinese-German Lung Cancer Forum takes place in Dresden. From 8th till 10th September 2016, 120 international …View Article
July 5, 2016
PEKKIP Oncology at ASCO in Chicago
From 3rd till 7th June, this year’s ASCO took place in Chicago – the world’s largest cancer congress. The congress …View Article
November 29, 2015
Review 7th Chinese German Lung Cancer Forum, Shanghai
At November 13th and 14th, the “8th Chinese German Lung Cancer Forum” took place in Shanghai. More than 700 international …View Article
November 20, 2015
Review Post WCLC 2015, Dresden
From 5th till 6th November 2015, the “Post World Conference on Lung Cancer 2015” took place in Dresden. The meet-up, …View Article
November 6, 2015
PEKKIP at the Chinese-German Lung Cancer Forum
Also this year PEKKIP Oncology Alliance is joining the 7th Chinese-German Lung Cancer Forum taking place in Shanghai on November …View Article
November 1, 2015
PEKKIP at the Post WCLC 2015 in Dresden
PEKKIP Oncology Alliance is happy to welcome you on November 5 and 6 at the second “Post-World Conference on Lung …View Article
August 19, 2015
In cooperation with various pharmaceutical companies PEKKIP Oncology Alliance organizes advisory boards in the context of different international scientific congresses. …View Article
April 21, 2015
PEKKIP at ChinaBio, Shanghai
ChinaBio® Partnering Forum is a Life Science Networking Event in Shanghai. The conference attracts BioTech- and Pharma executives from all …View Article
March 29, 2015
PEKKIP at BioEurope, Paris
BIO-Europe Spring® is a three-day partnering conference, that annually brings together the who’s who of BioTech-, Pharma and Venture-Captial Industry …View Article
PEKKIP Oncology Alliance AG – a PEKKIP Holding company
Your career at PEKKIP Oncology Alliance.
Our team is looking forward to get to know you.
Thank you for considering employment with PEKKIP Oncology Alliance AG. If you feel that your skills and experience are aligned to the career opportunities posted please e-mail your CV directly to email@example.com. Unsolicited applications are also welcome.
We thank all applicants for their interest, but only candidates chosen for an interview will be contacted.
We’ve one aim in mind: helping people by accelerating drug development.
Jingrui Yang – Senior Representative for PEKKIP Oncology Alliance in China
PEKKIP Oncology Alliance AG
Fon +49 6221 65570-0
Fax +49 6221 65570-22
Managing director: Ahmet Pekkip
Chairman of supervisory board: Dr Hans-Peter Gebhardt
Court of registry: District Court Mannheim, HRB 720105
Tax number: 32496/86360
VAT identification number: DE295810600